Nathan Connell: The Changing Landscape of von Willebrand Disease Diagnosis and Management
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared a post on Linkedln about a recent article he and his colleagues co-authored, published in Haemophilia, adding:
“In 2024, I traveled to Föglö in the Åland archipelago for the Seventh Åland Island Meeting on von Willebrand Disease.
I wrote then about the significance of returning to the place where Erik von Willebrand first described the disorder nearly a century ago.
It was a rare opportunity to connect the history of the field with the current work needed to improve diagnosis, treatment, and access for people living with VWD.
I am pleased to share that our meeting summary has now been published in Haemophilia Journal: ‘Seventh Åland Island Meeting on von Willebrand Disease.’
The manuscript captures several themes that remain central to the future of VWD care:
- VWD is common, heterogeneous, and still under-recognized, with diagnostic delays that continue to affect quality of life and treatment access.
- Bleeding assessment tools, newer VWF activity assays such as VWF and VWF, genotype-informed interpretation, and standardized diagnostic pathways are changing the diagnostic landscape.
- Women’s health remains a central priority, including heavy menstrual bleeding, pregnancy, postpartum hemorrhage, iron deficiency, and the need for stronger hematology–gynecology collaboration.
- Defining ‘severe VWD’ more consistently is essential for clinical decision-making, prophylaxis access, reimbursement, and clinical trial design.
- Emerging data support prophylaxis for selected patients with clinically severe VWD, while personalized and pharmacokinetic-guided approaches require further study.
- The next phase of progress will depend on multidisciplinary collaboration among clinicians, laboratory scientists, geneticists, biologists, patient communities, and industry partners.
I was grateful to contribute the section on navigating the diagnostic landscape in VWD, including the persistent challenge of delayed diagnosis, the appropriate role of bleeding assessment tools, and the need to adapt guideline-based diagnostic algorithms to real-world and differently resourced settings.
Thank you to Octapharma for supporting this meeting and making it possible for us to gather in Åland for such a thoughtful and productive discussion.
Congratulations and thanks to my coauthors and colleagues, including Riitta Lassila, Erik Berntorp, Ruben Bierings, Fernando Corrales-Medina, Augusto Federici, Veronica Flood, Floor Heubel-Moenen, Jill Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schön, Anish Sharda, Robert Sidonio, Alok Srivastava, Timea Szanto, and Angela Weyand.”
Title: Seventh Åland Island Meeting on von Willebrand Disease
Auhtors: Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales-Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel-Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp

Other posts featuring Nathan Connell on Hemostasis Today.
-
Nov 20, 2026, 12:29Thirunavukkarasu Angappan: Antithrombin in ECMO – Two Datasets, Two Opposite Answers
-
Nov 20, 2026, 11:38Muhammad Kashif: Therapeutic Plasma Exchange – Key Concepts at a Glance
-
Nov 20, 2026, 11:33Tyler McConville: Why Hemostatic Function Matters More Than Cell Counts in Trauma and Transfusion
-
Nov 20, 2026, 11:28Stéphanie Forté: Bringing Cutting-Edge Genomic and Proteomic Tools to Sickle Cell Disease Patients
-
Nov 20, 2026, 11:19EHC Urges Equal Early Diagnosis for Bleeding Disorders
-
Nov 20, 2026, 11:14Pushpinder Singh: How Do We Know if Haemodialysis is Effective?
-
Nov 20, 2026, 11:09Neel Patel: Honoured to Serve Across Five Faculty Roles at Hematocon 2026
-
Nov 20, 2026, 11:03Alok Khorana: First FXI Inhibitor Approved in the US
-
Nov 20, 2026, 06:51How YERM Shapes the Careers of Future Hematology Researchers – EHA